Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10805
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Patterson, Scott J | - |
dc.contributor.author | Angus, Peter W | - |
dc.date.accessioned | 2015-05-16T00:22:29Z | |
dc.date.available | 2015-05-16T00:22:29Z | |
dc.date.issued | 2009-06-01 | - |
dc.identifier.citation | Current Opinion in Organ Transplantation; 14(3): 225-30 | en_US |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/10805 | en |
dc.description.abstract | The established gold standard for prophylaxis against hepatitis B virus (HBV) recurrence post-liver transplant is combination hepatitis B immune globulin (HBIG) and lamivudine. This therapy reduces the risk of recurrence to less than 5% at 5 years; however, the cost of HBIG has led to the investigation of alternatives. This paper reviews the HBIG-sparing alternatives achieved with lamivudine and the prospects for the newer anti-HBV agents in post-liver transplant prophylaxis.When used with lamivudine as part of combination prophylaxis, low-dose intramuscular HBIG is equivalent to high-dose intravenous HBIG. There is recent evidence that in patients receiving HBIG/lamivudine, HBIG can be replaced with adefovir dipivoxil at 6-12 months post-liver transplant without precipitating recurrence. Furthermore, a recent study showed that primary prophylaxis with combination adefovir/lamivudine therapy without the use of long-term HBIG was effective and well tolerated as primary prophylaxis.Although there are few studies of potent newer anti-HBV agents such as entecavir or tenofovir being used as HBV prophylaxis, the properties of these drugs suggest that they should replace lamivudine within HBV prophylaxis regimes. | en_US |
dc.language.iso | en | en |
dc.subject.other | Adenine.administration & dosage.analogs & derivatives | en |
dc.subject.other | Administration, Oral | en |
dc.subject.other | Antiviral Agents.administration & dosage.adverse effects | en |
dc.subject.other | Drug Administration Schedule | en |
dc.subject.other | Drug Therapy, Combination | en |
dc.subject.other | Graft Survival.drug effects | en |
dc.subject.other | Guanine.administration & dosage.analogs & derivatives | en |
dc.subject.other | Hepatitis B.prevention & control.surgery | en |
dc.subject.other | Humans | en |
dc.subject.other | Immunoglobulins.administration & dosage | en |
dc.subject.other | Injections, Intramuscular | en |
dc.subject.other | Lamivudine.administration & dosage | en |
dc.subject.other | Liver Transplantation.adverse effects | en |
dc.subject.other | Nucleosides.administration & dosage.adverse effects | en |
dc.subject.other | Nucleotides.administration & dosage.adverse effects | en |
dc.subject.other | Organophosphonates.administration & dosage | en |
dc.subject.other | Secondary Prevention | en |
dc.subject.other | Treatment Outcome | en |
dc.title | Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Current Opinion in Organ Transplantation | en_US |
dc.identifier.affiliation | Victorian Liver Transplant Unit | en_US |
dc.identifier.doi | 10.1097/MOT.0b013e32832b1f32 | en_US |
dc.description.pages | 225-30 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/19373086 | en |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en |
local.name.researcher | Angus, Peter W | |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Gastroenterology and Hepatology | - |
crisitem.author.dept | Victorian Liver Transplant Unit | - |
crisitem.author.dept | Gastroenterology and Hepatology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.